Deals
Novartis and Unnatural Products did not specify which disease targets they’re going after, only noting that the latter’s macrocyclic platform can generate potentially next-generation therapies that could apply to cardiovascular conditions.
FEATURED STORIES
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Speaking on the sidelines of the J.P. Morgan Healthcare Conference, Novo business development executive Tamara Darsow said the company is gunning for obesity and diabetes assets.
Buying vaccine biotech Dynavax was an easy choice for Sanofi despite anti-vaccine moves by the Trump administration.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Oxford Immunotec Global PLC announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, and Matt McLaughlin, Chief Financial Officer, will be participating in two upcoming investor conferences.
Singapore molecular diagnostics groups INEX Innovations Exchange Pte. Ltd. (INEX) and Nova Satra Dx Pte. Ltd. (Nova Satra) announced the merger of the two companies to create INEX INNOVATE.
Race Oncology Limited announced the successful completion of a $1.45 million placement, led by prominent biotechnology investor Dr Daniel Tillett.
WuXi Biologics (Cayman) Inc. announced its unaudited interim results for the six months ended June 30, 2019.
Sernova Corp., a clinical-stage regenerative medicine company, is pleased to announce that it has completed a first closing of $2,333,500 of its non-brokered private placement, of which $64,000 was closed under the “Existing Shareholder Exemption.”
The company is seeking the funds to continue to drive the development of its lead candidates, nirogacestat, a gamma-secretase inhibitor for the treatment of desmoid tumors and PD-0325901, a MEK inhibitor for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas.
Auris Medical Holding Ltd. provided a business update and announced financial results for the first half of the 2019 financial year ended June 30, 2019.
InflaRx reported financial and operating results for the second quarter ended June 30, 2019.
Evotec SE reported financial results and corporate updates for the first half of 2019.
Addition of ImmunArray autoimmune testing assets, Nudge patient-engagement capabilities enhances diagnostic and patient support offerings